GLPwatch
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
NCT03311724 · Completed
Last updated 2026-05-28This study tests the medication tirzepatide in adults with type 2 diabetes to see how it affects their blood sugar levels over time.
Status Completed The study has finished.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 111 people
Who can join Ages 18–75 · all sexes
Timeline Started 2017-10 · est. completion 2018-04
Where 13 sites · United States
What this study is testing ClinicalTrials.gov NCT03311724 ↗
Description as written by the study sponsor.
The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.
Treatments tested
- Tirzepatide also known as LY3298176 Drug
Administered SC
- Placebo Drug
Administered SC
| Main thing measured | Change From Baseline in Haemoglobin A1c (HbA1c) |
|---|---|
| Sponsor | Eli Lilly and Company |
| Conditions studied | Type 2 Diabetes |
| GLP-1 drugs | tirzepatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03311724 ↗